Academic literature on the topic 'Sloan-Kettering Institute for Cancer Research'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Sloan-Kettering Institute for Cancer Research.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Sloan-Kettering Institute for Cancer Research"
1
Lipitz-Snyderman, Allison, Jessica Kennington, Brooke Hogan, et al. "Engaging Community-Based Cancer Physicians: Experience of the Memorial Sloan Kettering Cancer Center Cancer Alliance." Journal of the National Comprehensive Cancer Network 17, no. 9 (2019): 1083–87. http://dx.doi.org/10.6004/jnccn.2019.7295.
Full textAbstract:
Background: The proliferation of relationships between community health systems and academic medical centers has created a need to identify effective components of these models. This article reports on frontline physician experiences, with one such relationship established through the Memorial Sloan Kettering Cancer Center (MSK) Cancer Alliance. MSK created the Alliance with the goals of rapidly bringing the newest standards of care into community settings and increasing patient access to clinical trials in their local communities. Methods: Alliance leadership administered a 10-question anonymous survey to physicians treating patients with cancer across the 3 Alliance member health systems: Hartford HealthCare Cancer Institute, Lehigh Valley Cancer Institute, and Miami Cancer Institute at Baptist Health South Florida. The purpose of the survey was to identify opportunities to improve physician engagement. Results: There were 103 clinician respondents across Alliance members, of which 87 reported participation in a disease management team and were included in the final analysis. Most respondents reported high value from Alliance activities, such as attending MSK tumor boards (94%) and lecture series (96%), among those who reported them applicable. Across all respondents, most reported satisfaction with engagement opportunities, such as MSK physician participation in their institution’s meetings (76%). When asked where they would like to see increased engagement, the most commonly reported response was for more lecture series (45%). Most respondents (88%) reported that the Alliance led to practice change, either for themselves or for other clinicians at their institution. Many attributed this practice change to MSK disease-specific process measures. Conclusions: The activities most valued by community physicians were heavily physician relationship–based. The encouraging experience of the MSK Cancer Alliance suggests that activities involving physician investment may be effective for promoting practice change in the context of cross-institution relationships. Future research is needed in this area.
2
Kundra, Ritika, Hongxin Zhang, Robert Sheridan, et al. "OncoTree: A Cancer Classification System for Precision Oncology." JCO Clinical Cancer Informatics, no. 5 (March 2021): 221–30. http://dx.doi.org/10.1200/cci.20.00108.
Full textAbstract:
PURPOSE Cancer classification is foundational for patient care and oncology research. Systems such as International Classification of Diseases for Oncology (ICD-O), Systematized Nomenclature of Medicine Clinical Terms (SNOMED-CT), and National Cancer Institute Thesaurus (NCIt) provide large sets of cancer classification terminologies but they lack a dynamic modernized cancer classification platform that addresses the fast-evolving needs in clinical reporting of genomic sequencing results and associated oncology research. METHODS To meet these needs, we have developed OncoTree, an open-source cancer classification system. It is maintained by a cross-institutional committee of oncologists, pathologists, scientists, and engineers, accessible via an open-source Web user interface and an application programming interface. RESULTS OncoTree currently includes 868 tumor types across 32 organ sites. OncoTree has been adopted as the tumor classification system for American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE), a large genomic and clinical data-sharing consortium, and for clinical molecular testing efforts at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. It is also used by precision oncology tools such as OncoKB and cBioPortal for Cancer Genomics. CONCLUSION OncoTree is a dynamic and flexible community-driven cancer classification platform encompassing rare and common cancers that provides clinically relevant and appropriately granular cancer classification for clinical decision support systems and oncology research.
3
Naidoo, Jarushka, Xuan Wang, Kaitlin M. Woo, et al. "Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy." Journal of Clinical Oncology 35, no. 7 (2017): 709–17. http://dx.doi.org/10.1200/jco.2016.68.2005.
Full textAbstract:
Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. Methods Patients who received anti–PD-1/PD-L1 monotherapy or in combination with anti–cytotoxic T-cell lymphocyte associated antigen-4 mAb were identified at two institutions (Memorial Sloan Kettering Cancer Center: advanced solid cancers, 2009 to 2014, and Melanoma Institute of Australia: melanomas only, 2013 to 2015). Pneumonitis was diagnosed by the treating investigator; cases with confirmed malignant lung infiltration or infection were excluded. Clinical, radiologic, and pathologic features of pneumonitis were collected. Associations among pneumonitis incidence, therapy received, and underlying malignancy were examined with Fisher’s exact test as were associations between pneumonitis features and outcomes. Results Of 915 patients who received anti–PD-1/PD-L1 mAbs, pneumonitis developed in 43 (5%; 95% CI, 3% to 6%; Memorial Sloan Kettering Cancer Center, 27 of 578 [5%]; Melanoma Institute of Australia, 16 of 337 [5%]). Time to onset of pneumonitis ranged from 9 days to 19.2 months. The incidence of pneumonitis was higher with combination immunotherapy versus monotherapy (19 of 199 [10%] v 24 of 716 [3%]; P < .01). Incidence was similar in patients with melanoma and non–small-cell lung cancer (overall, 26 of 532 [5%] v nine of 209 [4%]; monotherapy, 15 of 417 v five of 152 [ P = 1.0]; combination, 11 of 115 v four of 57 [ P = .78]). Seventy-two percent (31 of 43) of cases were grade 1 to 2, and 86% (37 of 43) improved/resolved with drug holding/immunosuppression. Five patients worsened clinically and died during the course of pneumonitis treatment; proximal cause of death was pneumonitis (n = 1), infection related to immunosuppression (n = 3), or progressive cancer (n = 1). Radiologic and pathologic features of pneumonitis were diverse. Conclusion Pneumonitis associated with anti–PD-1/PD-L1 mAbs is a toxicity of variable onset and clinical, radiologic, and pathologic appearances. It is more common when anti–PD-1/PD-L1 mAbs are combined with anti–cytotoxic T-cell lymphocyte associated antigen-4 mAb. Most events are low grade and improve/resolve with drug holding/immunosuppression. Rarely, pneumonitis worsens despite immunosuppression, and may result in infection and/or death.
4
Markman, M., T. Hakes, R. Barakat, J. Curtin, L. Almadrones, and W. Hoskins. "Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer." Journal of Clinical Oncology 14, no. 3 (1996): 796–99. http://dx.doi.org/10.1200/jco.1996.14.3.796.
Full textAbstract:
PURPOSE To examine the short-term and long-term results of paclitaxel therapy in patients with advanced heavily pretreated, cisplatin-refractory ovarian cancer. PATIENTS AND METHODS The results of treatment for patients entered onto National Cancer Institute (NCI) Treatment Referral Center protocol 9103 at the Memorial Sloan-Kettering Cancer Center (MSKCC) were reviewed to evaluate toxicity, efficacy, and survival. RESULTS Of 46 individuals with measurable disease treated on the protocol at MSKCC, the objective response rate was only 4%. However, the 2- and 3-year survival rates for all 103 patients (including both measurable and nonmeasurable populations) entered onto this study at MSKCC were 18% and 11%, respectively. Twenty-one percent of patients received > or = six courses of paclitaxel, which suggests treatment-related stabilization of disease may have had a greater impact on the natural history of the malignancy than indicated by the objective response rate. CONCLUSION This experience supports the hypothesis that a more prolonged delivery of paclitaxel (ie, > six courses), a cell-cycle-specific cytotoxic agent with limited or no cumulative toxicity, may result in an improved therapeutic outcome in ovarian cancer. This concept will need to be tested in a randomized phase 3 clinical trial.
5
Tang, Jiaqi, Cody Gifford, Rohan Samarakoon та Paul Higgins. "Deregulation of Negative Controls on TGF-β1 Signaling in Tumor Progression". Cancers 10, № 6 (2018): 159. http://dx.doi.org/10.3390/cancers10060159.
Full textAbstract:
The multi-functional cytokine transforming growth factor-β1 (TGF-β1) has growth inhibitory and anti-inflammatory roles during homeostasis and the early stages of cancer. Aberrant TGF-β activation in the late-stages of tumorigenesis, however, promotes development of aggressive growth characteristics and metastatic spread. Given the critical importance of this growth factor in fibrotic and neoplastic disorders, the TGF-β1 network is subject to extensive, multi-level negative controls that impact receptor function, mothers against decapentaplegic homolog 2/3 (SMAD2/3) activation, intracellular signal bifurcation into canonical and non-canonical pathways and target gene promotor engagement. Such negative regulators include phosphatase and tensin homologue (PTEN), protein phosphatase magnesium 1A (PPM1A), Klotho, bone morphogenic protein 7 (BMP7), SMAD7, Sloan-Kettering Institute proto-oncogene/ Ski related novel gene (Ski/SnoN), and bone morphogenetic protein and activin membrane-bound Inhibitor (BAMBI). The progression of certain cancers is accompanied by loss of expression, overexpression, mislocalization, mutation or deletion of several endogenous repressors of the TGF-β1 cascade, further modulating signal duration/intensity and phenotypic reprogramming. This review addresses how their aberrant regulation contributes to cellular plasticity, tumor progression/metastasis and reversal of cell cycle arrest and discusses the unexplored therapeutic value of restoring the expression and/or function of these factors as a novel approach to cancer treatment.
6
Vo, B. T., B. Cody, Y. Cao, and S. A. Khan. "Differential role of Sloan-Kettering Institute (Ski) protein in Nodal and transforming growth factor-beta (TGF- )-induced Smad signaling in prostate cancer cells." Carcinogenesis 33, no. 11 (2012): 2054–64. http://dx.doi.org/10.1093/carcin/bgs252.
Full text
7
Huang, Yingying, Chuan-ben Chen, Yu Chen, et al. "Effect of CCND1 amplification on immunosuppression and the association with a poor prognosis to immune checkpoint inhibitors in solid tumors." Journal of Clinical Oncology 38, no. 15_suppl (2020): e15249-e15249. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15249.
Full textAbstract:
e15249 Background: CCND1 amplification relevant to malignant biological behavior exist in solid tumors. The prevalence and utility of CCND1 amplification as a biomarker for the clinical response to immune checkpoint inhibitors (ICIs) therapy is unknown. Methods: This study included three cohorts: Geneplus Institute ( n= 6536), The Cancer Genome Atlas ( n= 10562) and Memorial Sloan Kettering Cancer Center ( n= 106109). Comprehensive profiling was performed to determine the prevalence of CCND1 amplification and their correlation with the prognosis and the response to ICIs. Results: CCND1 amplification occurs in many cancer types, correlates with shorter overall survival and inferior outcomes with ICIs therapy. Transcriptomic analysis showed various degrees of immune cells exclusion, including cytotoxic cells, T cells, CD8+ T cells, DC cells, B cells in the tumor microenvironment (TME) in a CCND1 amplification population. The gene set enrichment analysis suggested that CCND1 amplification correlates with multiple aggressive, immunosuppressive hallmarks including epithelial mesenchymal transition, TGF-β signaling, KRAS signaling, PI3K/AKT/mTOR signaling, p53 pathway and hypoxia signaling in solid tumors. Conclusions: Our study indicated that CCND1 amplification may be a key point related to immunosuppression in TME and multiple malignancy hallmarks, and it hinders not only the natural host immune responses but also the efficacy of ICIs in solid tumors.
8
Gigoux, Mathieu, Roberta Zappasodi, Joseph Park, et al. "444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A470. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0444.
Full textAbstract:
BackgroundThe majority of JAK2V617F-negative myeloproliferative neoplasms (MPN) have disease-initiating frameshift mutations in calreticulin (CALR) resulting in a common novel C-terminal mutant fragment (CALRMUT), representing an attractive source of neoantigens for cancer vaccines. However, studies have shown that CALRMUT-specific T cells are rare in CALRMUT MPN patients, but the underlying reasons for this phenomenon are unknown.MethodsIn this study, we examine class-I major histocompatibility complex (MHC-I) allele frequency in CALRMUT MPN patients from two independent cohorts and observed that MHC-I alleles that present CALRMUT neoepitopes with high affinity are under-represented in CALRMUT MPN patients. We speculate that this is due to an increased chance of immune-mediated tumor rejection by individuals expressing one of these MHC-I alleles such that the disease never clinically manifests. As a consequence of this MHC-I allele restriction, we reasoned that CALRMUT MPN patients would not efficiently respond to cancer vaccines composed of the CALRMUT fragment, but could do so when immunized with a properly modified CALRMUT heteroclitic peptide vaccine approach.ResultsWe found that heteroclitic CALRMUT peptides specifically designed for CALRMUT MPN patient MHC-I alleles efficiently elicited a cross-reactive CD8+ T cell response in human PBMC samples otherwise unable to respond to the matched weakly immunogenic CALRMUT native peptides. We also modeled this effect in mice and observed that C57BL/6J mice, which are unable to mount an immune response to the human CALRMUT fragment, can mount a cross-reactive CD8+ T cell response against a CALRMUT-derived peptide upon heteroclitic peptide immunization and this was further amplified by combining the heteroclitic peptide vaccine with blockade of the immune checkpoint molecule PD-1.ConclusionsTogether, our data underscore the therapeutic potential of heteroclitic peptide-based cancer vaccines in CALRMUT MPN patients.Ethics ApprovalApproval was obtained for the use of patient-derived specimens and access to clinical data extracted from patient charts by the Institutional Review Boards at Memorial Sloan Kettering Cancer Center, the Dana-Farber Cancer Institute and the Massachusetts General Hospital, as well as by the Danish Regional Science Ethics Committee. Mouse experiments were performed in accordance with institutional guidelines under a protocol approved by the Memorial Sloan-Kettering Cancer Center Institutional Animal Care and Use Committee.
9
Lo, Serigne N., Jiawen Ma, Richard A. Scolyer, et al. "Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram." Journal of Clinical Oncology 38, no. 24 (2020): 2719–27. http://dx.doi.org/10.1200/jco.19.02362.
Full textAbstract:
PURPOSE For patients with primary cutaneous melanoma, the risk of sentinel node (SN) metastasis varies according to several clinicopathologic parameters. Patient selection for SN biopsy can be assisted by National Comprehensive Cancer Network (NCCN) and ASCO/Society of Surgical Oncology (SSO) guidelines and the Memorial Sloan Kettering Cancer Center (MSKCC) online nomogram. We sought to develop an improved online risk calculator using alternative clinicopathologic parameters to more accurately predict SN positivity. PATIENTS AND METHODS Data from 3,477 patients with melanoma who underwent SN biopsy at Melanoma Institute Australia (MIA) were analyzed. A new nomogram was developed by replacing body site and Clark level from the MSKCC model with mitotic rate, melanoma subtype, and lymphovascular invasion. The predictive performance of the new nomogram was externally validated using data from The University of Texas MD Anderson Cancer Center (n = 3,496). RESULTS The MSKCC model receiver operating characteristic curve had a predictive accuracy of 67.7% (95% CI, 65.3% to 70.0%). The MIA model had a predictive accuracy of 73.9% (95% CI, 71.9% to 75.9%), a 9.2% increase in accuracy over the MSKCC model ( P < .001). Among the 2,748 SN-negative patients, SN biopsy would not have been offered to 22.1%, 13.4%, and 12.4% based on the MIA model, the MSKCC model, and NCCN or ASCO/SSO criteria, respectively. External validation generated a C-statistic of 75.0% (95% CI, 73.2% to 76.7%). CONCLUSION A robust nomogram was developed that more accurately estimates the risk of SN positivity in patients with melanoma than currently available methods. The model only requires the input of 6 widely available clinicopathologic parameters. Importantly, the number of patients undergoing unnecessary SN biopsy would be significantly reduced compared with use of the MSKCC nomogram or the NCCN or ASCO/SSO guidelines, without losing sensitivity. An online calculator is available at www.melanomarisk.org.au .
10
Sauter, Craig, W. Jeffrey Baker, Elizabeth Rodriguez, et al. "QIM19-134: Improving Access to Bone Marrow Transplant in the Community: The Memorial Sloan Kettering Cancer Alliance Shared Care Program." Journal of the National Comprehensive Cancer Network 17, no. 3.5 (2019): QIM19–134. http://dx.doi.org/10.6004/jnccn.2018.7247.
Full textAbstract:
Background: Memorial Sloan Kettering Cancer Center (MSK) created the MSK Cancer Alliance in 2014, a dynamic and bidirectional collaboration with high-quality community providers to enhance access to state-of-the-art cancer care close to home. Hartford HealthCare Cancer Institute (HHC), joined the MSK Cancer Alliance as the first member in 2014. Research suggests that bone marrow transplant (BMT) is an underutilized definitive therapy (Yao et al, Biol Blood Bone Marrow Transplant 2013) for patients with hematologic malignancies and the timing of a referral for transplant has significant impact on patient outcomes (National Marrow Donor Program, available at: https://bethematchclinical.org/transplant-indications-and-outcomes/additional-outcomes/timing-impact-on-outcomes/). MSK and HHC developed the BMT Shared Care program to improve access to transplant, ensure BMT specialist consults for appropriate candidates occur during initial treatment planning, reduce burdensome travel for patients by facilitating care locally, and enhance seamless coordination between local oncologists and BMT providers from initial consult through post-transplant care. Methods: To achieve these goals, MSK and HHC physicians, nurses, and staff created a program that includes: HHC hiring a BMT nurse, who trained for 4 weeks at MSK, and works with MSK counterparts to create a streamlined referral process, pretransplant care at HHC, and travel logistics to MSK; MSK and HHC physicians hold virtual tumor boards to jointly evaluate patients and provide BMT consults at the optimal time; onsite lectures and observer-ships focused on advances in BMT, supportive care, and management of complications like graft versus host disease, leading to the integration of additional clinical services like infectious disease and dermatology; and research, including an MSK clinical trial open at HHC to identify and understand barriers to transplant in the community for patients with newly diagnosed or relapsed acute leukemia. Results: Since November 2015, HHC has referred 86 patients for BMT consult through this Shared Care program, with 35 patients transplanted or receiving immune effector cells (IEC) to date. Conclusions: The BMT Shared Care program effectively facilitates the referral and transplant of appropriate patients while allowing them to receive much of their pre- and post-transplant care in their local communities. Collaboration between BMT nurse coordinators and robust physician engagement are essential to this program. Future opportunities include expanding the use of telemedicine, enhancing electronic data sharing, quantifying and analyzing patient satisfaction, and expanding BMT research at HHC.
Books on the topic "Sloan-Kettering Institute for Cancer Research"
1
Doctored results: The suppression of laetrile at Sloan-Kettering Institute for Cancer Research. Equinox Press, Inc., 2014.
2
United States. President's Cancer Panel. Meeting. President's Cancer Panel Meeting: Transcript of proceedings, January 24, 2005, Memorial Sloan-Kettering Cancer Center, New York, New York. National Cancer Institute, 2005.
3
Breitbart, William S., and Shannon R. Poppito. Meaning-Centered Group Psychotherapy for Patients with Advanced Cancer. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199837250.001.0001.
Full textAbstract:
The importance of spiritual well-being and the role of "meaning" in moderating depression, hopelessness and desire for death in terminally-ill cancer and AIDS patients has been well-supported by research, and has led many palliative clinicians to focus on the development of non-pharmacologic interventions that can help their patients address these issues. Individual Meaning-Centered Group Psychotherapy (IMCP), an intervention developed and rigorously tested by the Department of Psychiatry & Behavioral Sciences at Memorial Sloan-Kettering Cancer Center, is a seven-week program based around the work of Viktor Frankl, and which utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. Patients are assigned readings and homework that are specific to each session's theme and which are utilized in each session. While the focus of each session is on issues of meaning and purpose in life in the face of advanced cancer and a limited prognosis, elements of support and expression of emotion are inevitable in the context of each group session.
Book chapters on the topic "Sloan-Kettering Institute for Cancer Research"
1
Peter J., Neumann, Cohen Joshua T., and Ollendorf Daniel A. "Other US Value Assessment Frameworks." In The Right Price. Oxford University Press, 2021. http://dx.doi.org/10.1093/oso/9780197512883.003.0007.
Full textAbstract:
The Institute for Clinical and Economic Review (ICER) is not the only organization that has attempted to bring value assessment to the United States to address high pharmaceutical prices. With the federal government’s continued reluctance to embrace formal value assessment during the 2010s, other organizations introduced their own approaches. These groups included medical societies with a history of evidence-based clinical guideline development. Examples include the American Society of Clinical Oncology, National Comprehensive Cancer Network, and the American College of Cardiology/American Heart Association. Memorial Sloan Kettering Cancer Centre weighed in with its online “DrugAbacus” tool. This chapter argues that these other frameworks have serious limitations, including a focus on a single clinical area, use of arbitrary scoring systems, and a lack of transparency. ICER has therefore emerged as the dominant framework for assessment of drug pricing and coverage policy.
2
Duva, Melissa Masterson, Wendy G. Lichtenthal, Allison J. Applebaum, and William S. Breitbart. "Meaning-Centered Psychotherapy." In Psycho-Oncology, edited by William S. Breitbart, Phyllis N. Butow, Paul B. Jacobsen, Wendy W. T. Lam, Mark Lazenby, and Matthew J. Loscalzo. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190097653.003.0062.
Full textAbstract:
Existential concerns carry significant distress, particularly among patients with advanced cancer. For patients who are facing death, a sense of meaning—and the preservation of that meaning—is not only clinically and existentially important but also central to providing holistic, high-quality end-of-life care. Nearly two decades ago, the authors’ research group at Memorial Sloan Kettering Cancer Center began to understand that a meaning-centered approach to psychosocial care was imperative to alleviate the existential distress that plagued many patients with advanced cancer. Based on Viktor Frankl’s work on the importance of meaning and principles of existential psychology and philosophy, they developed Meaning-Centered Psychotherapy (MCP) to help patients with advanced cancer sustain or enhance a sense of meaning, peace, and purpose in their lives in the face of terminal cancer. This chapter provides an overview of MCP in working with patients with cancer. It summarizes the ever-growing body of research that has demonstrated the effectiveness of MCP in improving meaning, spiritual well-being, and quality of life and in reducing psychological distress and despair at end of life. Adaptations of MCP for other purposes and populations, such as cancer survivors, caregivers, and bereavement, are mentioned but are elaborated on in other specific chapters related to these issues in this textbook.
3
Taber, Douglass F. "C–O Ring Construction: The Smith Synthesis of (+)-18-epi-Latrunculol A." In Organic Synthesis. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190646165.003.0046.
Full textAbstract:
James A. Bull of Imperial College London showed (Angew. Chem. Int. Ed. 2014, 53, 14230) that the malonate 1 could readily be cyclized to the oxetane 2. Davide Ravelli of the University of Pavia functionalized (Adv. Synth. Catal. 2014, 356, 2781) the α position of the oxetane 3 with 4, leading to 5. Frank Glorius of the Westfälische Wilhelms-Universität Münster hydrogenated (Angew. Chem. Int. Ed. 2014, 53, 8751) the furan 6 to give 7 in high ee. Jia-Rong Chen and Wen-Jing Xiao of Central China Normal University converted (Eur. J. Org. Chem. 2014, 4714) the initial Henry adduct from 8 into the cyclic ether 9. Anil K. Saikia of the Indian Institute of Technology, Guwahati cyclized (J. Org. Chem. 2014, 79, 8592) the ene–yne 10 to the ketone 11. Richard C. D. Brown of the University of Southampton developed (Org. Lett. 2014, 16, 5104) a chiral auxiliary that effectively directed the oxidative cyclization of the diene 12 to 13. The chiral auxiliary could be recovered and reused. K. A. Woerpel of New York University showed (Org. Lett. 2014, 16, 3684) that, depending on the solvent, 15 could be added to 14 to give either 16 or 17. Samuel J. Danishefsky of Columbia University and the Memorial Sloan-Kettering Cancer Center also observed (Chem. Eur. J. 2014, 20, 8731) a marked solvent effect on the diastereoselectivity of the reduction of 18 to 19. Xiaoming Feng of Sichuan University added (Chem. Eur. J. 2014, 20, 14493) the ketone 20 to Danishefsky’s diene 21 to give 22 in high ee. Jhillu Singh Yadav of the Indian Institute of Chemical Technology effected (Tetrahedron Lett. 2014, 55, 3996) intramolecular opening of the oxetane of 23 to give, with clean inversion, the cyclic ether 24. Chun-Yu Ho of the South University of Science and Technology, taking advantage (J. Org. Chem. 2014, 79, 11873) of the superior chelating ability of the allyl ether, selectively cyclized 25 to 26. Xuegong She of Lanzhou University used (Angew. Chem. Int. Ed. 2014, 53, 10789) a gold catalyst to convert 27 into the eight-membered ring ether 28.
Conference papers on the topic "Sloan-Kettering Institute for Cancer Research"
1
Vo, BaoHan T., Bianca Cody, Yang Cao, Shafiq A. Khan та Center for Cancer Research and Therapeutic De. "Abstract 1064: Sloan-Kettering Institute (Ski) protein plays distant roles in activation of Smad proteins in response to nodal and TGF-β in prostate cancer cells". У Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1064.
Full text